Lymphoma, Large-Cell, Diffuse Clinical Trial
Official title:
Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma
The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell lymphoma who responded to ACVBP regimen. Our goal is to obtain a 15% increase of event-free survival at 2 years.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00379574 -
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
|
Phase 1/Phase 2 | |
Terminated |
NCT00514722 -
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
|
N/A | |
Terminated |
NCT00135499 -
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00511043 -
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00823719 -
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
|
Phase 2 | |
Completed |
NCT01014208 -
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
|
Phase 3 | |
Completed |
NCT00001237 -
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
|
Phase 2 | |
Terminated |
NCT00498914 -
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
|
Phase 2 | |
Completed |
NCT00137995 -
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
|
Phase 3 | |
Completed |
NCT00498043 -
A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
|
Phase 2 | |
Completed |
NCT00622388 -
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
|
Phase 2 | |
Completed |
NCT00561379 -
Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab
|
N/A |